PharmaLeaders.com

News. Resources. Community.

  • Features
  • Channels
    • Biotech Channel
    • Clinical Channel
    • CME Channel
    • Compliance Channel
    • Device Channel
    • HIMSS Channel
    • Marketing Channel
    • Pharma Channel
    • R&D Channel
    • Telehealth Channel
    • Training Channel
  • Events
  • On Demand
  • White Papers
  • Vendors
    • Biotech Vendors
    • Clinical Vendors
    • CME Vendors
    • Compliance Vendors
    • Device Vendors
    • Marketing Vendors
    • Pharma Vendors
    • R&D Vendors
    • Training Vendors
  • Contributors

AFT and Salus Pharmaceuticals sign agreement for pain treatment Maxigesic IV

02/02/2023 by PharmaLeaders Aggregator

Under the terms of the partnership deal between the companies, Hyloris will receive a share on any revenues related to product, such as royalties, license fees, milestone payments, The post AFT and Salus Pharmaceuticals sign agreement for pain treatment Maxigesic IV appeared first on Pharmaceutical Business review. … [Read more...]

GSK receives orphan drug designation for Benlysta to treat systemic sclerosis

02/02/2023 by PharmaLeaders Aggregator

Initially, the FDA approved Benlysta for the treatment of active systemic lupus erythematosus (SLE). GSK noted that it is the first and only approved biologic for SLE as The post GSK receives orphan drug designation for Benlysta to treat systemic sclerosis appeared first on Pharmaceutical Business review. … [Read more...]

TScan Therapeutics receives FDA clearance for IND applications

02/01/2023 by PharmaLeaders Aggregator

Serving as the primary IND for TScan’s solid tumour programme, T-Plex will enable customised combinations of T cell receptor (TCR)-engineered T cell therapies (TCR-T) to be given to The post TScan Therapeutics receives FDA clearance for IND applications appeared first on Pharmaceutical Business review. … [Read more...]

US FDA grants fast track designation to Artiva’s lead programme AB-101

02/01/2023 by PharmaLeaders Aggregator

AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use along with monoclonal antibodies or innate-cell engagers in the out-patient environment. Artiva The post US FDA grants fast track designation to Artiva’s lead programme AB-101 appeared first on Pharmaceutical Business review. … [Read more...]

Genexine receives FTD for DNA vaccine to treat advanced cervical cancer

01/31/2023 by PharmaLeaders Aggregator

MFDS concluded that GX-188E met the criteria for this designation after assessing the complete set of Phase II results from the clinical trial that was recently completed in The post Genexine receives FTD for DNA vaccine to treat advanced cervical cancer appeared first on Pharmaceutical Business review. … [Read more...]

Next Page »
  • Facebook
  • LinkedIn
  • Twitter

Choose Your Channel

Receive event announcements and special reports directly in your inbox.
  • This field is for validation purposes and should be left unchanged.

Upcoming Events

  1. 6th CAR-TCR Summit Europe

    February 21 - February 23
  2. 7th Virtual Clinical Trials Summit

    May 16 - May 17

View All Events

  • About Us
  • Sponsorship
  • Join Our Team
  • Contact Us

Copyright © 2023 PharmaLeaders.com. All rights reserved.